Phase 12 Study of REGN17372 with Linvoseltamab for Adults with Relapsed or Refractory Multiple Myeloma Assessing Safety, Tolerability, and Early Anti-Tumor Effects

What this Trial Is About

Researchers are evaluating a drug called REGN17372 in combination with linvoseltamab in adults with relapsed or refractory multiple myeloma, a type of cancer that affects plasma cells. This trial is the first time REGN17372 will be given to humans, aiming to understand its safety, how it can be dosed with linvoseltamab, and how well this combination works compared to linvoseltamab alone. The study also investigates side effects, drug levels in the blood, the bodys immune response to the drugs, and impacts on quality of life. Participants receive either REGN17372 combined with linvoseltamab or linvoseltamab alone following a dosing schedule defined by the study protocol. This includes phases 1 and 2, where dosing regimens and tolerability are assessed. The study tracks how these treatments affect the disease and participant well-being over time. During the trial, participants undergo regular medical assessments including safety monitoring for side effects and treatment responses measured by established criteria. Blood samples are collected to measure drug concentrations and antibodies against the drugs. Quality of life questionnaires help understand the participant experience. The study lasts up to five years to monitor long-term effects and outcomes.

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma